Precision drug to stimulate immune system against some cancers
Gustave Roussy's researchers found an unkown ability to PARP inihibitors - a precision cancer drug used against breast and ovarian cancer - to stimulate the immune system. This study suggests to developp new combinaisons of treatments with immunotherapy.
Gustave Roussy at the ESMO 2018 Congress
This year, the European Society for Medical Oncology (ESMO) will take place in Munich, Germany, from 19 to 23 October. It is Europe’s biggest cancer congress and the number of delegates increases year-on-year. Experts from all over the world visit the congress to share the latest clinical innovations in oncology. Around 20,000 delegates from 130...
Predicting the response to immunotherapy with artificial intelligence
A study published in The Lancet Oncology establishes for the first time that artificial intelligence can process medical images to extract biological and clinical information. By designing an algorithm and developing it to analyse CT scan images, medical researchers at Gustave Roussy, CentraleSupélec, Inserm, Paris-Sud University and TheraPanacea...
Gustave Roussy at the ASCO Annual Meeting 2018
As in every year for more than half a century, the world's leading Oncologists are meeting in Chicago early in June to discuss the latest clinical advances in the field. Gustave Roussy will, of course, be among the main protagonists at this Congress.